

Multi-pathway signaling analysis using a synthetic phosphopeptide panel, standardized sample preparation kits and SureQuant internal standard targeted quantitation

Aaron S. Gajadhar¹, Bhavin Patel², Penny Jensen², Sebastien Gallien^{3,4}, Romain Huguet¹, Kay Opperman², John C Rogers², Andreas Huhmer¹, Daniel Lopez-Ferrer¹

¹Thermo Fisher Scientific, San Jose, CA; ²Thermo Fisher Scientific, Rockford, IL; ³Thermo Fisher Scientific, PMSC, Cambridge, MA; ⁴Thermo Fisher Scientific, Paris, France.

Purpose

To develop a universal phosphopeptide enrichment and internal standard (IS)-guided LC-MS acquisition workflow for reproducible, sensitive and high-density absolute quantification of biologically relevant phosphorylation sites in multiple biological pathways.

Methods

Leveraged Sequential Metal Oxide Affinity Chromatography (SMOAC) phosphopeptide enrichment, isotopically-labeled phosphopeptides and Thermo Scientific™ SureQuant™ IS-triggered acquisition to detect and quantify 138 pSTY targets simultaneously using Thermo Scientific™ Orbitrap Exploris™ 480 Mass Spectrometer.

Results

Compared to traditional discovery-based proteomics approaches for pSTY analysis, the SureQuant Multi-pathway phosphopeptide acquisition workflow outperformed DDA and PRM for detection of the multi-pathway phosphopeptides panel.



Orbitrap Exploris 480 MS

Introduction

Challenge


- Phosphopeptide analysis of multiple signaling pathways is analytically challenging.
- Phosphopeptides account for <1% of total peptides in a sample and require enrichment!

Methods

- Currently, low-yield, low specificity of phosphopeptide enrichment, and irreproducible detection of functionally important phosphopeptides prohibits routine pathway proteomics.

New Approach

- SureQuant IS-triggered targeted detection strategy
- 138 phosphopeptide internal standard panel
- SMOAC



Sample Preparation

- 2 mg HeLa + Nocadazole-treated cell line
- Thermo Scientific™ EasyPep™ Maxi MS Sample Prep kit
- 1 pmol of 138 heavy-labeled Multi-Pathway Phosphopeptide Standard
- High-Select TiO₂ Kit and High-Select Fe-NTA Kit
- Thermo Scientific™ Pierce™ Peptide Desalting Spin Columns
- 20% of total phospho-enrichment elution was used per injection

LC/MS Analysis

- Column: Thermo Scientific™ EASY-Spray™ C18 HPLC columns (ES804)
- HPLC: Thermo Scientific™ EASY-nLC™ 1200 system
- Gradient: 60 minutes
- MS: Orbitrap Exploris 480 MS
- Method: SureQuant IS-triggered targeted acquisition
- Method: Data-dependent acquisition for discovery run
- Method: PRM targeted analysis for benchmarking

Data Analysis

- Proteome Discoverer software for DDA analysis
- Skyline software for PRM and SureQuant analysis

Results – Multi-Pathway Phosphopeptide Profiling

Compare DDA, PRM and SureQuant quantitation of 138 functionally-relevant phosphopeptide targets

- Replicate injections of same phosphopeptide elution to compare methods
- DDA: 30K MS2, 54 ms IT, ~12Hz, favoring sensitivity
- PRM: Constrain cycle time for 8 points peak, 2.5 min RT window
- SureQuant: Constrain cycle time for 8 points peak, No RT scheduling needed


Multi-Pathway 138 Phosphopeptide Standard

AQUA Ultimate Grade,
Heavy labeled

<u>Sites</u>	<u>Occupancy</u>
88 Serine	132 single
25 Threonine	5 double
29 Tyrosine	1 triple

85 Unique Proteins
142 Phosphorylation Sites



Cellular Phosphorylation Networks



Results – Discovery Acquisition Schemes Do Not Adequately Monitor Pathway Targets

DDA Misses Most Multi-pathway Standards and Endogenous Targets Despite Detectable Amounts


- SMOAC enrichment captures broad pool of phosphopeptides.
- Poor detection of functionally relevant endogenous phosphopeptides from the multi-pathway panel.
- DDA stochastic sampling likely resulted in missed detection of desired multi-pathway targets.



Results – Typical Targeted Methods Don't Provide Sensitivity For High-Density Panels

SureQuant Dynamic MS2 Control Allows ~6X More Fill Time and Maintains Appropriate Sampling Rates


- Real-time recognition of target elution time.
- Dynamic control of high-sensitivity, high-fill time MS2 scans at the precise time of target elution.
- Dynamic fill-time management allows duty cycles to be maintained within appropriate ranges.



Results – Increased Fill Time = Higher Measurement Sensitivity

SureQuant Multi-Pathway Phosphopeptide Detection Outperforms DDA And PRM


- SMOAC enrichment provides reproducible enrichment of multi-pathway targets.
- SureQuant targeted analysis enabled most comprehensive detection.
- Reference standard detection provides clarity about 'missing values' for endogenous targets.



Results – SureQuant Measurement Sensitivity More Sample Insight

Endogenous phosphopeptides can be quantified at 10X lower levels than PRM

- SureQuant targeted acquisition enabled quantitation of more low-abundant phosphorylated signaling pathway proteins than PRM.
- Due to significantly improved measurement sensitivity.
- Amol/ug levels of detection.



Conclusions

- SureQuant IS-triggered targeted acquisition on Orbitrap Exploris 480 MS facilitates reliable and robust quantitative measurements.
- The multi-pathway phosphopeptide panel coupled with standardized sample preparation, SMOAC enrichment, and SureQuant acquisition provides a turnkey approach for comprehensive signaling pathway analysis.
- Modular combination of SMOAC enrichment, IS phosphopeptide panels, and SureQuant targeting creates the opportunity of fit-for-purpose signaling pathway assays.

TRADEMARKS/LICENSING

© 2020 Thermo Fisher Scientific Inc. All rights reserved. SEQUEST is a trademark of the University of Washington. All other trademarks are the property of Thermo Fisher Scientific and its subsidiaries. This information is not intended to encourage use of these products in any manner that might infringe the intellectual property rights of others. For Research Use Only. Not for use in diagnostic procedures